Ceritinib efficiently induces cell death in CCA cells through the activation of both apoptosis and autophagy pathways, irrespective of ALK mutation or expression status by targeting multiple kinases leading to the inhibition of the Akt signaling pathway. The gene discussed is ALK; the disease is cholangiocarcinoma.